Approval · Notice of Compliance 25699 · 2021
CELESTONE SOLUSPAN: Notice of Compliance 25699
Issued April 20, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25699
- Date
- April 20, 2021
- Company
- Organon Canada Inc.Kirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Change in product ownership
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CELESTONE SOLUSPAN | 00028096 | Marketed |
Medicinal ingredients
- BETAMETHASONE 3 MG per ML
- BETAMETHASONE ACETATE 3 MG per ML